TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27300278

Group type: EXPERIMENTAL
Intervention: Increasing HIT group (n = 23)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Decreasing HIT group (n = 20)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mixed HIT group (n = 20)
Number of subjects: 63
Study: 24738705

Group type: EXPERIMENTAL
Intervention: Bereavement vignette and self-report items measuring grief expectations
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Bereavement vignette and self-report items measuring social distance
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Gender of the bereaved and circumstances of death
Number of subjects: 348
Study: 23429813

Group type: EXPERIMENTAL
Intervention: Reminiscence program intervention using a life-story approach
Number of subjects: 135

Group type: COMPARATOR
Intervention: Active control group participating in casual discussions
Number of subjects: 135

Group type: COMPARATOR
Intervention: Passive control group participating in casual discussions
Number of subjects: 135
Study: 20810606

Group type: EXPERIMENTAL
Intervention: Evening meals composed of high-amylose barley kernels or high-β-glucan barley kernels
Number of subjects: 15

Group type: COMPARATOR
Intervention: Evening meal with white wheat bread
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Standardized breakfast following evening test meals
Number of subjects: 15
Study: 17688420

Group type: EXPERIMENTAL
Intervention: Normal-sodium diet (120 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Number of subjects: 232

Group type: COMPARATOR
Intervention: Low-sodium diet (80 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Number of subjects: 232
Study: 16182672

Group type: EXPERIMENTAL
Intervention: Immediate intervention (training course for parents)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Delayed access to the course (control group)
Number of subjects: 51
Study: 12462500

Group type: EXPERIMENTAL
Intervention: Negative stressor condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative stress condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative stress condition with elevated Beck Depression Inventory scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated depression scores
Number of subjects: 0
Study: 10350104

Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cold blood cardioplegia (Group B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subgroup 1 (TnT peak < 1 ng/ml)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subgroup 2 (TnT peak between 1 and 3 ng/ml)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subgroup 3 (TnT peak > 3 ng/ml)
Number of subjects: 43
Study: 7859141

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 600 mg/day plus acyclovir (ACV) 4,800 mg orally per day
Number of subjects: 93

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) 600 mg/day plus placebo
Number of subjects: 93
Study: 1838032

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7171073

Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy (MMTP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active alcoholics (AA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactive alcoholics (IA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonalcoholics (NA)
Number of subjects: 0
Study: 6423586

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.4 mg/ml saline)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (saline infusion 1 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (infusion control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All trials (naloxone, control, placebo)
Number of subjects: 6
Study: 30155949

Group type: EXPERIMENTAL
Intervention: Long interval (LI) group (surgery after 8 weeks)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Classical interval (CI) group (surgery within 8 weeks)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Long interval (LI) group
Number of subjects: 327

Group type: COMPARATOR
Intervention: Classical interval (CI) group
Number of subjects: 327
Study: 27143669

Group type: EXPERIMENTAL
Intervention: Universal decolonization treatment with chlorhexidine bathing and nasal mupirocin
Number of subjects: 136
Study: 24589827

Group type: EXPERIMENTAL
Intervention: Self-reported hysterectomy at recruitment questionnaire (RQ)
Number of subjects: 48215

Group type: EXPERIMENTAL
Intervention: Self-reported hysterectomy at interview format (IF)
Number of subjects: 48215

Group type: EXPERIMENTAL
Intervention: Self-reported hysterectomy at both RQ and IF
Number of subjects: 48215
Study: 22571408

Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg intravenously every 90 days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (500 mg calcium with 400 iu vitamin D daily)
Number of subjects: 118
Study: 20047702

Group type: EXPERIMENTAL
Intervention: Brief intervention plus a health information leaflet
Number of subjects: 103

Group type: COMPARATOR
Intervention: Health information leaflet alone
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 103
Study: 19140508

Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actovegin
Number of subjects: 0
Study: 15841664

Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12423628

Group type: EXPERIMENTAL
Intervention: Acipimox (an inhibitor of lipolysis) with GH
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acipimox without GH
Number of subjects: 7

Group type: COMPARATOR
Intervention: GH without Acipimox
Number of subjects: 7

Group type: COMPARATOR
Intervention: Neither GH nor Acipimox
Number of subjects: 7
Study: 9862828

Group type: EXPERIMENTAL
Intervention: L‐NMMA 2 mg/kg/h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L‐NMMA 4 mg/kg/h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L‐NMMA 0.5 mg/kg/h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study: 7537524

Group type: EXPERIMENTAL
Intervention: Combination therapy of all-trans retinoic acid (ATRA) and granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination therapy of ATRA, G-CSF, erythropoietin (Epo), and tocopherol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination therapy of ATRA and cytokines
Number of subjects: 18
Study: 2095747

Group type: EXPERIMENTAL
Intervention: Group A (drank three or more cups of coffee/day for two months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group B (abstained from coffee for two months)
Number of subjects: 21
Study: 7033013

Group type: EXPERIMENTAL
Intervention: Sulphadiazine/trimethoprim (1 g daily for 10 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sulphamethoxazole/trimethoprim (1.92 g B.I.D for 10 days)
Number of subjects: 54
Study: 31568829

Group type: EXPERIMENTAL
Intervention: EMAT-guided management (n=114)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Symptom-guided management (n=111)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: EMAT-guided management in patients with predischarge %EMAT > 15% (n=85)
Number of subjects: 225
Study: 31088559

Group type: EXPERIMENTAL
Intervention: Low-intensity mobile phone text message brief intervention
Number of subjects: 598

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 598
Study: 29605360

Group type: EXPERIMENTAL
Intervention: Intraoperative treatment with paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27468022

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.1 mg/kg i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GV-26 acupuncture with electrical stimulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control treatment (0.9% saline, at 0.1 ml/kg i.m.)
Number of subjects: 6
Study: 24285605

Group type: EXPERIMENTAL
Intervention: Alcohol septal ablation (ASA)
Number of subjects: 459
Study: 23184162

Group type: EXPERIMENTAL
Intervention: Application of fluoride gel using a toothbrush
Number of subjects: 10

Group type: COMPARATOR
Intervention: Application of fluoride gel using a tray (control)
Number of subjects: 10
Study: 20651607

Group type: EXPERIMENTAL
Intervention: Hip position at 30° external rotation (H30)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hip position at 50° external rotation (H50)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hip position at neutral (H0)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Knee flexion at 60-90° (C3 and E3)
Number of subjects: 10
Study: 17397734

Group type: EXPERIMENTAL
Intervention: Stromal hydration (using fortified balanced salt solution [BSS Plus])
Number of subjects: 80

Group type: COMPARATOR
Intervention: No stromal hydration
Number of subjects: 80
Study: 15718401

Group type: EXPERIMENTAL
Intervention: Handgrip exercise (arm) at 60% maximum WR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Knee‐extensor exercise (leg) at 60% maximum WR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Comparison of shear rates at 60% maximum WR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Comparison of vessel diameter and shear rate
Number of subjects: 6
Study: 11794191

Group type: EXPERIMENTAL
Intervention: Left ventricular assist device
Number of subjects: 129

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 129
Study: 9394977

Group type: EXPERIMENTAL
Intervention: IgE-associated cutaneous diseases (AD and scabies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dermopathic lymph node from AD patient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal lymphatic tissue
Number of subjects: 0
Study: 7895789

Group type: EXPERIMENTAL
Intervention: Reduced visual cues during movement sequence
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fast movement sequence with visual cues
Number of subjects: 14
Study: 3540329

Group type: EXPERIMENTAL
Intervention: Feedback of the results of a screening instrument (the General Health Questionnaire)
Number of subjects: 0
Study: 30925125

Group type: EXPERIMENTAL
Intervention: S‐1 plus docetaxel
Number of subjects: 915

Group type: COMPARATOR
Intervention: S‐1 alone
Number of subjects: 915
Study: 28423233

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 468

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 468
Study: 25782693

Group type: EXPERIMENTAL
Intervention: Home-based telemonitored robotic-assisted therapy (HMP) combined with home exercise program (HEP) for 3 hours/day, 5 days/week for 8 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Home exercise program (HEP) only at identical dosage
Number of subjects: 99
Study: 23887354

Group type: EXPERIMENTAL
Intervention: Raltegravir associated with tenofovir/emtricitabine or abacavir/lamivudine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Raltegravir in protocol compliant population
Number of subjects: 39
Study: 21823854

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 62
Study: 19514485

Group type: EXPERIMENTAL
Intervention: Conservative treatment (close reduction and immobilization in a plastofit splint)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Operative treatment (percutaneous fixation by Kirschner‐wires)
Number of subjects: 22
Study: 16705315

Group type: EXPERIMENTAL
Intervention: KSHV latent antibodies
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: KSHV lytic antibodies
Number of subjects: 256

Group type: COMPARATOR
Intervention: Anti-EBV antibodies
Number of subjects: 256

Group type: COMPARATOR
Intervention: Antibody levels against EBV
Number of subjects: 256

Group type: COMPARATOR
Intervention: Antibodies against KSHV (latent and lytic)
Number of subjects: 256
Study: 15298070

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer generation antidepressants
Number of subjects: 0
Study: 11339515

Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam (15 mg)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Oral meloxicam (15 mg)
Number of subjects: 346
Study: 9401312

Group type: EXPERIMENTAL
Intervention: Serotonergic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8260542

Group type: EXPERIMENTAL
Intervention: Intravenously administered immunoglobulins (IVIG)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no IVIG treatment)
Number of subjects: 116
Study: 3920093

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Iron chondroitinsulfuric acid complex
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ferritin alone or associated with folinic acid and cobamamide
Number of subjects: 69
Study: 31170306

Group type: EXPERIMENTAL
Intervention: K-SADS-PL-DSM-5-T
Number of subjects: 150
Study: 28777459

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 607

Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 607
Study: 26304789

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) and Muscle Energy Technique (MET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Muscle Energy Technique (MET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dry Needling (DN)
Number of subjects: 60
Study: 24666774

Group type: EXPERIMENTAL
Intervention: Preoperative education intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 20
Study: 22689290

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) taper
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Continuation pharmacotherapy or naturalistic follow-up after TMS taper
Number of subjects: 61
Study: 20367092

Group type: EXPERIMENTAL
Intervention: Fully etched test implants
Number of subjects: 112

Group type: COMPARATOR
Intervention: Hybrid control implants
Number of subjects: 112
Study: 18723908

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg (low dose group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 1.0 g/kg (high dose group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (0.5 g/kg and 1.0 g/kg)
Number of subjects: 38
Study: 15944533

Group type: EXPERIMENTAL
Intervention: Iterative reconstruction with combined compensation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Filtered backprojection (FBP)
Number of subjects: 87
Study: 12408208

Group type: EXPERIMENTAL
Intervention: Patient-peer intervention (face-to-face encouragement from peer interventionists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-provider intervention (face-to-face encouragement from provider interventionists)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care condition (open access to physical activity programming)
Number of subjects: 0
Study: 10490161

Group type: EXPERIMENTAL
Intervention: 5 microg x kg(‐1) clonidine p.o.
Number of subjects: 39

Group type: COMPARATOR
Intervention: No clonidine
Number of subjects: 39
Study: 8739021

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Squalene 860 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin 10 mg + Squalene 860 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 8384980

Group type: EXPERIMENTAL
Intervention: Group A: 10 million international units (MIU) of interferon alpha-2b (IFN) six times a week for eight weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group B: 10 MIU IFN six times a week for four weeks followed by three times a week for an additional eight weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group C: 10 MIU IFN six times a week for two weeks followed by three times a week for 12 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Group A: 10 MIU IFN six times a week for eight weeks
Number of subjects: 126
Study: 3700343

Group type: EXPERIMENTAL
Intervention: Combination therapy with lecithin and ergoloid mesylates
Number of subjects: 7
Study: 29897597

Group type: EXPERIMENTAL
Intervention: High-frequency (20 Hz) rTMS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 59
Study: 26969660

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (loading dose with 50 mg/kg over 10 min and then 15 mg/kg/h by continuous infusion)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 84
Study: 23337214

Group type: EXPERIMENTAL
Intervention: Community-wide Cardiovascular Health Awareness Program (CHAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (19 communities without CHAP)
Number of subjects: 39
Study: 21834964

Group type: EXPERIMENTAL
Intervention: Health and weight cohort trials facility
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Ongoing information as to the natural history of the condition and treatment as usual
Number of subjects: 20000
Study: 19350305

Group type: EXPERIMENTAL
Intervention: Long-term chemoradiotherapy (RT/CTx) as standard treatment for locally advanced rectal cancer.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality controlled principles of radical surgery (partial vs total mesorectal excision) followed by adjuvant chemotherapy.
Number of subjects: 0
Study: 17352947

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation for 8 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Baseline (pre-treatment)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post-treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dietary iron intake
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mean corpuscular volume and hemoglobin
Number of subjects: 33
Study: 15122749

Group type: EXPERIMENTAL
Intervention: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated 8 weeks after onset of acute hepatitis.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, followed by interval IFN therapy (3 times weekly for 20 weeks).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated after 1 year of observation.
Number of subjects: 30
Study: 11345493

Group type: COMPARATOR
Intervention: J0 (no fire jacket)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: J1 (leather jacket)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: J3 (textile jacket without membrane)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: J5 (textile jacket with Kermel HTA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: J2 (textile jacket with membrane)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: J4 (textile jacket with Kermel HTA)
Number of subjects: 6
Study: 9257777

Group type: EXPERIMENTAL
Intervention: grepafloxacin (400 mg)
Number of subjects: 351

Group type: COMPARATOR
Intervention: cefixime (400 mg)
Number of subjects: 351
Study: 8314485

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 26
Study: 3534597

Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumpectomy followed by definitive radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 30244988

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 26658703

Group type: EXPERIMENTAL
Intervention: Physician empathy (PE)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Match between patients' preferred and perceived decision-making styles
Number of subjects: 71
Study: 24411489

Group type: EXPERIMENTAL
Intervention: Intervention Formula (IF) - 1.89 g protein/100 kcal with α‐lactalbumin (ALAB) and LC‐PUFA
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control Formula (CF) - 2.30 g protein/100 kcal with standard whey and no LC‐PUFA
Number of subjects: 213
Study: 22337145

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 151

Group type: COMPARATOR
Intervention: Pain education
Number of subjects: 151
Study: 20423560

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18942247

Group type: EXPERIMENTAL
Intervention: Lactated ringer 20 ml/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% hypertonic saline 4 ml/kg followed by lactated ringer 10 ml/kg/hr
Number of subjects: 60
Study: 16412917

Group type: EXPERIMENTAL
Intervention: Extensive anterior capsule polishing
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (non-polishing)
Number of subjects: 54
Study: 12519743

Group type: EXPERIMENTAL
Intervention: Motilin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12119980

Group type: EXPERIMENTAL
Intervention: Community-developed lead poisoning prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control census tracts
Number of subjects: 0
Study: 8917053

Group type: EXPERIMENTAL
Intervention: Continued treatment with antiepileptic drugs (AEDs)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Discontinued or reduced treatment before the occurrence of their first seizure
Number of subjects: 409

Group type: COMPARATOR
Intervention: Discontinued treatment
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Overall cohort of patients
Number of subjects: 409
Study: 1836615

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine and Amitriptyline
Number of subjects: 0